Journal profile · CLINICAL NEUROLOGY
Degenerative Neurological and Neuromuscular Disease
ISSN 1179-9900
Degenerative Neurological and Neuromuscular Disease: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 7 (journal website); JCR Q1 (journal website); fully open access; APC charged, amount not published; median 118 days to acceptance (22 articles, last 24 months); acceptance rate 13% (journal website); 9 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Degenerative Neurological and Neuromuscular Disease is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Multiple Sclerosis Research Studies, Amyotrophic Lateral Sclerosis Research and Parkinson's Disease Mechanisms and Treatments, together about 30.4% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
An international, peer-reviewed, open access journal focusing on research into the biological and clinical basis of degenerative neurological diseases including Multiple Sclerosis, Huntington’s disease, Alzheimer’s Disease, Parkinson’s Disease and Friedreich’s ataxia. Specific topics covered in the journal include: Natural history, epidemiology, detection and screening Pathophysiology, causative agents and vectors, cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing agents, including combination therapies Complementary and alternative medicine Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations
From the journal's Aims & Scope
Research area (LetPub): CLINICAL NEUROLOGY
Editor-in-chief Thomas MüllerPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Multiple Sclerosis Research StudiesMedicine14.4%
- Amyotrophic Lateral Sclerosis ResearchMedicine8.4%
- Parkinson's Disease Mechanisms and TreatmentsMedicine7.6%
- Genetic Neurodegenerative DiseasesNeuroscience7.6%
- Neurogenetic and Muscular Disorders ResearchMedicine6.3%
- Alzheimer's disease research and treatmentsMedicine5.9%
- Neurological disorders and treatmentsMedicine5.9%
- Peripheral Neuropathies and DisordersMedicine5.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Clinical Neurology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCILetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 7Publisher website ·
- 5-year impact factor (publisher) 2025
- 7Publisher website ·
- h-index
- 30OpenAlex ·
- i10-index
- 72OpenAlex ·
- 2-year mean citedness
- 11.19OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 9LetPub ·
- Downloads per year (publisher)
- 28,553Publisher website ·
Articles by year OpenAlex count · 155 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 10 | 10 | 2 |
| 2025 | 9 | 9 | 30 |
| 2024 | 12 | 12 | 315 |
| 2023 | 9 | 9 | 76 |
| 2022 | 11 | 11 | 159 |
| 2021 | 6 | 6 | 108 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
118 daysMedian, submission to acceptance · P25–P75 106 days – 159 days
- Acceptance to online
- median 17 days (22 articles)
- Submission to online
- median 153 days
- Sample
- 22 articles with submission and acceptance dates (22 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Acceptance rate (publisher)
- 13%Publisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics
- Publication ethics
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- ISSN
- 1179-9900
- Official links
- Journal homepage ↗OpenAlex
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Degenerative Neurological and Neuromuscular Disease
What CAS zone is Degenerative Neurological and Neuromuscular Disease in?
In the 2025 upgraded edition of the CAS Journal Ranking, Degenerative Neurological and Neuromuscular Disease is in Zone 4 of Medicine, and in Zone 4 of the minor category Clinical Neurology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Degenerative Neurological and Neuromuscular Disease?
The journal's website gives an impact factor of 7 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 30.
How long does peer review take at Degenerative Neurological and Neuromuscular Disease?
Based on the dates recorded on 22 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 106–159 days); the journal's website gives an acceptance rate of 13%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Degenerative Neurological and Neuromuscular Disease in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Degenerative Neurological and Neuromuscular Disease?
According to LetPub and DOAJ records, Degenerative Neurological and Neuromuscular Disease is indexed in ESCI.
Is Degenerative Neurological and Neuromuscular Disease open access, and what is the APC?
Degenerative Neurological and Neuromuscular Disease is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .